When it comes to developmental drugs, there's a lot of rumors and speculation thrown around about a drug's ultimate success or failure in clinical trials. When the time comes for that hard data, share prices are bound to soar or plummet in a big way. That's what happened today with BioMarin (NASDAQ: BMRN), which published phase 3 data around its drug treating an ultra-rare disorder called Morquio A syndrome. Follow along in the video as Brenton Flynn and Max Macaluso discuss today's news and a couple more companies in a similar situation to BioMarin.
Brenton Flynn owns shares of Sarepta Therapeutics. Max Macaluso owns now shares of the companies mentioned.The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend BioMarin Pharmaceutical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Shares of Amplify Snack Brands Soar 70% on Hershey Acquisition Agreement
In a move to diversify its products, Hershey agreed to acquire Amplify Snack Brands for $12 per share.
Why Shares of Seven Stars Cloud Group Are Soaring Today
Cryptocurrency mania is driving up the value of this unprofitable company.
3 Stocks I'd Hate to Buy
These oil stocks still have a long way to go before they can catch up with the competition.